| Website | vasogenix.net |
| Category | BioTech |
| Phone | (913) 888-4773 |
| Employees |
| TOTAL | $400k |
| FUNDING TOTAL | $400k |
| Venture Round Kansas Bioscience Authority | $400k |
VasoGenix Pharmaceuticals, Inc., is developing intravenous (IV) and controlled release drug treatments for addressing Heart Failure (“HF”) and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs. VasoGenix is initially focusing on a major unmet critical need in Acute Decompensated Heart Failure (“ADHF”), when the symptoms of HF become severe enough to require hospitalization.
